Target intelligence / Profile preview

T-type calcium channel subunit alpha-1H (Cav3.2)

Target
Cav3.2
Molecular classification
Ion channel, Voltage-gated calcium channel
01

Overview

T-type calcium channel subunit alpha-1H (Cav3.2) is a voltage-gated, low voltage-activated calcium channel expressed broadly in the central and peripheral nervous systems, heart, and other tissues. It is encoded by the gene CACNA1H and forms the ion-conducting pore of the channel. Cav3.2 channels are distinguished by their ability to open near resting membrane potentials, allowing them to play vital roles in regulating neuronal excitability, pacemaker activity, hormone secretion, and pain signaling. Cav3.2 is highly phosphorylated in vivo, and its function is modulated by kinases and phosphatases. Dysfunction or dysregulation of Cav3.2 has been linked to neurological and cardiovascular diseases, especially neuropathic pain and absence epilepsy. Pharmacological inhibition of Cav3.2 is a promising therapeutic strategy for pain and epilepsy, but safety concerns exist due to its widespread physiological roles[1][2][3][5][7].

Other names
Cav3.2T-type calcium channel alpha-1H subunitVoltage-dependent T-type calcium channel subunit alpha-1HCACNA1H (gene name)Low voltage-activated calcium channel Cav3.2TTCC Cav3.2
02

Mechanism of action

Blockade of calcium influx via the Cav3.2 channel, leading to reduced neuronal excitability and inhibited action potential firing (analgesia, anticonvulsant action)[5][3]. Allosteric inhibition via binding to central cavity or fenestrations of the channel pore (state-dependent block)[5].

03

Biological functions

Regulation of neuronal excitabilityPacemaker activity (cardiac and neuronal)Hormone secretionMuscle contractionCell proliferationCell cycle progressionNociception (pain perception)
04

Disease associations

Neuropathic painEpilepsyAbsence epilepsyCancerCardiovascular diseaseNeuropsychiatric and neurodegenerative disorders
05

Safety considerations

Off-target cardiovascular effects due to physiological Cav3.2 roles in cardiac pacemaking and vascular tone[1]Potential interference with normal hormone secretion or neuronal function if blocked systemically[1][3]
06

Interacting drugs

TTA-A2

7 more in the full profile.

07

Biomarkers

Upregulated or dysregulated expression correlated with neuropathic pain and certain epilepsies (potential biomarker for disease state or progression)[7][3]

Beyond the preview

Go deeper on T-type calcium channel subunit alpha-1H (Cav3.2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T-type calcium channel subunit alpha-1H (Cav3.2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call